Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Millenium

- PMLiVE

Takeda’s Entyvio recommended by NICE for bowel disease

But must supply the drug at a discounted rate to the NHS

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

Takeda appoints Christophe Weber as its new CEO

Frenchman had been widely expected to succeed Yasuchika Hasegawa

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

- PMLiVE

Takeda grows in Turkey with Neutec subsidiary acquisition

Will acquire Toplam Kalite for up to 300m Turkish lira

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

EU flag

Half a million cancer patients in EU use targeted drugs

New data also shows breast and lung cancers are among the most treated in Europe

Roche Basel Switzerland

Roche acquires cancer biobank firm Signature Diagnostics

Marks Swiss firm's fifth deal this year to expand its molecular diagnostics business

- PMLiVE

Takeda’s ‘oral Velcade’ clears first phase III hurdle

Ixazomib shows early stage promise for myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links